Economics evaluation of CANPAIN Fesability Study
In October 2018, the UK’s National Institute for Health and Care Excellence (“NICE”) issued a call for evidence to evaluate the safety and clinical efficacy of cannabis-based medicines for use in humans. In response, Celadon drew up plans for its own clinical trial, which it called CANPAIN. In August 2023, following a three-month feasibility study, the NHS Research Ethics Committee approved the CANPAIN trial for up to 5,000 patients.
After completing the feasibility study, Celadon commissioned YHEC to carry out a comprehensive and independent review of the data generated, and to construct an early economic model. YHEC’s findings underscore the safety, tolerability and effectiveness of Celadon’s cannabis-based medicines when delivered via an inhalation device for individuals suffering from non-cancer chronic pain.
These findings pave the way for the forthcoming CANPAIN trial which will generate additional safety, efficacy and economic data needed for full regulatory approval. Clintex continues in preparation for deployment of the CTI platform in the live trial once fully approved and the trial commences.
More info on the Celadon CANPAIN trial can be found here :
https://celadonpharma.com/rns-reach-early-economic-analysis-of-feasibility-study-data/
Follow Us:
· Website: https://www.clintex.io/
· Medium: https://medium.com/@clintexcti
· Twitter: https://twitter.com/clintexcti
· Telegram: http://t.me/clintexcti
· Youtube: https://www.youtube.com/c/ClintexCTI
· LinkedIn: https://www.linkedin.com/company/eclintex-ltd/
· Reddit: https://www.reddit.com/r/clintexcti
